Clinical Trials Sponsored by Otsuka Pharmaceuticals

Total 19756 results

Otsuka Pharmaceutical Co., Ltd.

Completed

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cerebral Infarction

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

Gastroparesis

United States
Otsuka Pharmaceutical, Inc., Philippines

Completed

Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room

Asthma

Philippines
Otsuka Beijing Research Institute
Otsuka Pharmaceutical Co., Ltd.

Unknown

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Non-Hodgkin's Lymphoma(NHL) | Multiple Myeloma(MM)

Hong Kong
Korea Otsuka International Asia Arab
Korea Otsuka Pharmaceutical Co., Ltd.; Zhejiang Otsuka Pharmaceutical Co.,...

Completed

Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy

Stomach Ulcer

China, Korea, Republic of
Otsuka Beijing Research Institute
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Hypovolemic Hyponatremia

China
University of Michigan
Otsuka Pharmaceuticals

Withdrawn

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

Heart Failure

United States
Otsuka Beijing Research Institute
Zhejiang Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia

Schizophrenia

China
Otsuka Beijing Research Institute
Zhejiang Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

Cerebral Infarction

China
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Canada Pharmaceutical Inc.; Lundbeck Canada Inc.

Completed

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Major Depressive Disorder

Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder (JUNIPER)

Major Depressive Disorder

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Recruiting

Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab. (MCTSRPMS)

Acute Gastritis | Chronic Gastritis

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Poland, Bulgaria, France
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Poland, Puerto Rico
Otsuka Pharmaceutical Factory, Inc.
Celerion

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

Obesity

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Post Traumatic Stress Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

Smoking Cessation

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety

Peripheral Artery Disease

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Borderline Personality Disorder

United States, Spain, Ukraine
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease

Chronic Occlusive Arterial Disease

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Drug-drug Interaction

Australia
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics (MAESTRO)

Schizophrenia | Antipsychotics | Long-Acting Injection | LAI | Aripiprazole

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Adult ADHD

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Tourette's Disorder

Germany, United States, Bulgaria, Romania, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Taiwan, Korea, Republic of, Mexico, Canada, Hungary
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Germany, Taiwan, Korea, Republic of, Mexico, Hungary, Bulgaria, Ukraine, Romania, Canada
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

Tourette's Disorder (TD)

United States, Canada, Hungary
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

ABF Tourette's Disorder Post Marketing Surveillance Study

Tourette's Disorder

Korea, Republic of
Duke University
Otsuka America Pharmaceutical

Terminated

A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

Post Traumatic Stress Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Pletaal SR Post Marketing Observational Study (PLTSRPMOS)

Cerebral Infarction | Ischemic Symptoms

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure (AQUATIC)

Heart Failure With Hyponatremia

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina (STELLA)

Vasospastic Angina

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation (CADENCE 215)

Atrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation

United States, Italy, Germany, Netherlands, Spain, United Kingdom
Northwestern University
Otsuka America Pharmaceutical

Completed

Effects of Tolvaptan in Healthy Adults

Healthy

United States

Clinical Trials Sponsored by Otsuka Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations